Update in Rheumatoid Arthritis - PowerPoint PPT Presentation

Update in rheumatoid arthritis
1 / 58

  • Uploaded on
  • Presentation posted in: General

Update in Rheumatoid Arthritis. Gregory Gardner, M.D. Gilliland-Henderson Professor of Medicine Division of Rheumatology University of Washington. Outline of Discussion. Pathophysiology Clinical Features Treatment Update Perioperative Management. Rheumatoid Arthritis. Pathophysiology.

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.

Download Presentationdownload

Update in Rheumatoid Arthritis

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript

Update in rheumatoid arthritis

Update in Rheumatoid Arthritis

Gregory Gardner, M.D.


Professor of Medicine

Division of Rheumatology

University of Washington

Outline of discussion

Outline of Discussion

  • Pathophysiology

  • Clinical Features

  • Treatment Update

  • Perioperative Management

Rheumatoid arthritis

Rheumatoid Arthritis


Rheumatoid arthritis demographics

Rheumatoid arthritis demographics

  • Autoimmune disease

  • Affects 1-2% of US population

  • 1st degree relative has double the risk

  • Women:Men 3:1

  • Occurs in two peaks:-Women during child bearing years-Men and women after age 60

Treating ra think bolero

Treating RA: think Bolero

N Engl J Med. 1990;322:1277–1289

J Rheumatol. 1996;239(suppl 44)2-4

Early 1990 RA immunologically staged by Harris (modified)

  • Stage 0 -1 - Benign autoimmunity to early RA; antigen processed/presented to T-cells; autoantibody production

  • Stage 2 - T cells proliferate & induce B cell proliferation. New blood vessels develop as a scaffold for proliferating synovitis. Acute inflammation in synovial fluid

  • Stage 3 - Marked synovial proliferation and inflammation develop with production of of cytokines

  • Stage 4 - Synovitis polarized into aggressively invasive front of macrophages and synovial cells that begins irreversible destruction of cartilage, ligaments and bone

  • Stage 5 - Progressive loss of articular cartilage & bone; tendon/ligamenous attenuation and loss; joint deformity

Genetic issues in ra

Genetic issues in RA

  • Genetic factors account for 50-60% of RA riskand environmental factor account for 40-50%

    • Shared epitope (SE) on 3rd hypervariable region on the HLA DR beta 1 chain, amino acid sequences 67-74, associated with susceptibility and severity of RA

  • The presence of anti-citrullinated peptide antibodies (ACPA ie anti-CCP) is the strongest predictor of developing rheumatoid arthritis; ACPA are also prognostic

    • Citrulline results from deimination of arginine; peptides with citrulline are immunogenic

    • In high risk populations, a long period of benign autoimmunity can proceed the onset of active RA

    • Anti-CCP antibodies my be present before RA develops

Structure function of hla molecule

Structure/functionof HLA molecule

Fig 1

Fig 2

Figure 1 is representation of structure of the HLA class II molecule present on and antigen presenting cells. Figure 2 shows the position of the shared epitope on the HLA DR molecule. Figure 3 illustrates the function of the class II molecule

Fig 3

ACR and Hochberg 2008

Update in rheumatoid arthritis

Benign autoimmunity: Specific auto-antibodies may precede the symptoms of rheumatoid arthritisNielen et al. Arthritis Rheum 2004;50:380

  • Study of 79 RA pts who had donated blood several times prior to onset of RA

  • 67% RF + 6 yrs after Dx; no data for CCP

  • 2100 control sera: 1.1% + for RF; 0.6% + for CCP

Environmental issues in ra

Environmental issues in RA

  • Are genetic mechanism responsible for the development of the benign autoimmune state and the inability to control the immune activation once initiated?

  • Are environmental factors responsible for initiating citrullination of peptides that genetic factors then react to?

  • Current environmental risk factors that appear to play a role in RA include by leading to citrullination of proteins

    • Smoking

    • Periodontal disease

Is rheumatoid arthritis caused by an environmental agent from the new world

Is rheumatoid arthritis caused by an environmental agent from the New World?


Rothschild BM, et al: Semin Arthritis Rheum 1992;22:181

Antiquity of rheumatoid arthritis

Antiquity of rheumatoid arthritis

  • Paucity of reports of RA in medical literature prior to the 1800’s; first clear case reported in 1676 by Sydenham

  • Rothschild et al examined 35,000 European skeletal remains without finding an example of RA-like Dz

    • Gout, osteoarthritis, ankylosing spondylitis etc. common

  • RA found in Pre-Colombian skeletons in N America

    • Especially in Tennessee, Ohio, Alabama, and Kentucky

    • Prevalence: 7% female, 3% males

Rothschild BM, et al: Semin Arthritis Rheum 1992;22:181

Update in rheumatoid arthritis

RA in European art: Siebrandus Sixtius, Dutch Priest 1631J Dequeker Ann Rheum Dis. 1992 April; 51(4): 561–562

European contact with north american ra

European contact with North American RA

Numerous NW Tribes with RA










Can we treat earlier klareskog et al nature clinical practice rheumatology 2006 2 425

Can we treat earlier?Klareskog et al. Nature Clinical Practice Rheumatology 2006;2:425

Rheumatoid arthritis1

Rheumatoid Arthritis

Clinical Features

2010 acr eular ra criteria

2010 ACREULAR/RA Criteria

6/10 points

Needed for


Small joints:




2-5 MTPs


> 3x ULN

Ddx of inflammatory polyarthritis

DDx of Inflammatory Polyarthritis

  • Rheumatoid arthritis

  • SLE - systemic features, + ANA/ENA

  • Psoriatic arthritis - rash, dactylitis

  • Viral arthritis ie parvovirus - more pain than swelling, rash, season

  • Polyarticular gout

  • Other CTD - other systemic features ie Raynaud’s, myositis, etc…

Joint distribution

Joint Distribution

  • Cervical spine

  • Shoulders

  • Elbows

  • Wrists

  • Hands

    • PIPs

    • MCPs


  • Hips

  • Knees

  • Ankles

    • Tibiotalar

    • Subtalar

  • Feet

    • MTPs

Earliest ra

Earliest RA

Ra hands late

RA Hands Late

Ra feet

RA Feet

Rheumatoid arthritis extra articular disease

Rheumatoid Arthritis:Extra-Articular Disease

Pulmonary Nodules

Scleritis in RA

Rheumatoid Vasculitis



RA nodule or gouty tophus?

Other complication of ra

Other complication of RA

  • Felty’s syndrome

    • Leukopenia, splenomegaly, RA

    • Infections, leg ulcers

  • C1-C2 subluxation

    • Neck pain, myelopathy

    • C spine flexion/extension views, MRI

  • Septic arthritis

    • Large joints, fewer systemic symptoms

    • Staph > Strep > gram negatives

    • Morbidity/mortality high

  • Tendon ruptures

    • Especially ring/little finger extensor tendons

Rheumatoid factor

Rheumatoid Factor

  • Rheumatolgic DiseaseRA, SLE, Sjogren’s, MCTD, PM/DM, Cryoglobulinemia

  • Infectious DiseaseSBE, TB, Syphilis, Hep C

  • OtherAging, IPF, Cirrhosis, Sarcoidosis, Waldenstrom’s

IgM Rheumatoid


IgG Fc Region

Points to remember!

-High level; worse prognosis

-May take months to appear

-20-30% of RA Pts never develop

-Not specific for RA

Anti ccp acpa


  • Antibodies to Cyclic Citrullinated Peptide (CCP) have a sensitivity of 78% and specificity of 96% for RA

  • 40% of “seronegative RA” are anti-CCP +

  • Level of CCP is directly correlated with the development of erosions

    • Negative , low-moderate (35-200) or high CCP (>200)

    • OR of radiographic progression vs CCP negative RA pts after10 yrs

      • Negative 1.0

      • Low-moderate 3.2

      • High 15.2

  • Other ACPA being investigated for utility in diagnosis and prognosis

Schellekens. Arthritis Rheum 2000;43:155

Imaging in ra

Imaging in RA

  • 5th MTP may show earliest changes in RA

  • RA X-ray findings:

    • Osteopenia

    • Marginal erosions

    • Jnt space narrowing

  • Ultrasound

  • MRI

Joint erosions in ra from bad to worse

Progressive X-ray changes in RA

Joint Erosions in RA: From Bad to Worse

Prediction model for erosive vs nonerosive ra early in disease course

Prediction Model for Erosive vs Nonerosive RA Early in Disease Course

524 consecutive patients with early arthritis; total score corresponds to predictive value for erosive vs nonerosive arthritis given the presence of persistent RA. Visser H et al. Arthritis Rheum. 2002;46:357-365; Visser H. Best Pract Res Clin Rheumatol. 2005;19:55-72.

Rheumatoid arthritis2

Rheumatoid Arthritis

Treatment Issues

Therapy for rheumatoid arthritis circa 1989

Therapy for Rheumatoid Arthritis circa 1989

  • Medications

    • Gold

    • Penicillamine

    • Hydroxychloroquine

    • Sulfasalazine

    • New drug, methotrexate

  • Treatment philosophy

    • Pyramid with sequential DMARD monotherapy

    • “Rheumatoid arthritis is a disabling but otherwise benign disease”

Rheumatoid arthritis circa 1989

Rheumatoid Arthritis Circa 1989

  • Frequent complications

    • Rheumatoid vasculitis

    • C1-C2 subluxation

    • Felty’s syndrome

    • Extensor tendon rupture

    • Septic arthritis

  • Pathophysiology of RA

    • Macrophage mediated disease

Update in rheumatoid arthritis

Outcome of RA over 20 years in 112 consecutive patients by functional class and mortality Scott DL et al. Lancet 1987;1108-1111

“The concept of remission-inducing drugs is fallacious. Early treatment may be advantageous, but the prognosis of RA in not good”

Business as usual was not working

Business as usual was not working

  • > 90% of RA patients have erosions after 2 yrsFuchs HA, et al: J Rheumatol 1989;16:585-591

  • 5 - 10% of RA patients become disabled each yrKushner I: J Rheumatol 1989;16:1-4

  • Only 18% of RA patients achieve a period of remission during the course of their disease.Wolfe F, Hawley DJ:J Rheumatol 1988;12:245-252

  • Median life expectancy decreased 4 yrs for men and 10 yrs for women with RAMitchell DM, et al: Arthritis Rheum 1986;29:706-713

Update in rheumatoid arthritis

“What we need in RA is a drug for which one does not need a statistician to see the beneficial effects”

Irving Kushner, M.D.

J Rheumatol 1989;16:1-4

Update in rheumatoid arthritis

“Time and comparative observations will be needed to show the optimum combination of drugs and whether step down bridge concept will achieve the sought for and presently unobtainable goal of early and sustained control of inflammation, improved quality of life and prevention of bone and joint damage.”

J Rheumatol. 1989;16:565-7

Changes in treatment approaches to ra

Changes in Treatment Approaches to RA


Combination therapy

Early intervention

Pyramid inversion

Treatment pyramid

Single-drug Rx












Ra t reatment themes 2011

RA treatment themes 2011

  • Early recognition, early institution of therapy especially with those with poor prognostic markers

    • Presence of erosions

    • High titer anti-CCP/RF

  • Treat to DAS (disease activity score) or some other measure of disease activity (SDAI, CDAI etc)

  • Methotrexate mainstay in most pts; dose to 15-20 mg/week

  • Consider early institution of biologic therapy

  • Strategies for using biologics under study ieinitial therapy with subsequent withdrawlvs add (discussed below)

Non biologic dmards for ra

Non-Biologic DMARDs for RA

  • Methotrexate

    • 7.5-25 mg/week po or sc

    • ETOH restriction, avoid pregnancy, folic acid

  • Leflunomide

    • 10-20 mg poqd

    • Avoid pregnancy, liver toxicity

  • Sulfasalazine

    • 500 mg 2 po bid

    • Sulfa allergies, agranulocytosis, azospermia

  • Hydroxychloroquine

    • 200-400 mg poqd (6.5mg/kg)

    • Rash, retinal toxicity

Biologic therapies 2011

Biologic Therapies 2011

  • Anti-TNF agents

    • Etanercept

    • Adalimumab

    • Infliximab

    • Certozilumab

    • Golimumab

  • Anti-B cell agent

    • Rituximab

  • Anti-T cell agent

    • Abatacept

  • Anti-IL-6 receptor antagonist

    • Tocilizumab

  • Coming attractions

    • Jak-2 inhibitors

    • Anti-IL-17 therapy

Monitoring dmards

Monitoring DMARDS

  • Hydroxychloroquine

    • Baseline eye exam, repeat at 5 yrs then every yr

  • Sulfasalazine

    • Baseline CBC LFTs; repeat q month time 3 then every 3 mo

  • Methotrexate

    • Baseline CBC, creatinine, LFTs, CXR, Hep B &C; CBC LFTs q mo x 6 mo then every 1-3 mos thereafter

  • Leflunomide

    • Baseline CBC, creatinine, LFTs, Hep B&C; CBC LFTs monthly for 6 mos then 1-3 mos thereafter

  • TNF inhibitors

    • Baseline CBC LFTs, Hep B (ok for Hep C!), PPD; CBC q mo x 3 then q 6 mos; consider monitoring for PPD (Quantaferon) conversion

Treating to clinical goal results in better outcomes ticora grigor c et al lancet 2004 364 263 269

Intensive treatmentgroup (n = 55)


Routine case group (n = 55)




Disease Activity Score












Treating to clinical goal results in better outcomes (TICORA) Grigor C, et al. Lancet. 2004;364:263-269

Mean DAS Scores Over Time

Total Sharp Score Progression

Routine Rx 8.5

Intensive Rx 4.5

P < 0.0001,intensive vs routine after month 3.

Comet emery lancet 2009 372 375 382

COMETEmery. Lancet 2009;372:375-382

MTX vs MTX plus etanercept in early RA; Rx 52 wks

542 pts with early RA (<2 yrs) and MTX naïve

MTX alone vs MTX+ETN with remission being primary endpoint

SAE is 12% combo vs 13% MTX alone

Update in rheumatoid arthritis

PREMIER study: radiographic changes of combination TNF+Mtx better than Mtx alone (RA pts with < 3 yrs of disease and MTX naïve)Breedveld FC, et al. Arthritis Rheum. 2006;54:26-37

Sharp Units

Update in rheumatoid arthritis

†p<0.05 vs. etanercept

‡p<0.05 vs. etanercept

TEMPO Study: Mean Change in Total Sharp Score From Baseline at 2 Years1



Mean Change From Baseline



1 Year

2 Years


*Total Sharp Score is based on combined scores of joint erosions in the hands on a scale of 0 to 5, feet on a scale of 0 to 10 (0=no damage), and joint space narrowing in hands and feet on a scale of 0 to 4 (0=no narrowing).

Klareskog L, et al. Lancet. 2004;363:675-681.

Healing of erosions

Healing of Erosions


42 y/o woman with 10 yrHx

of RA. On etanercept since

Note filling of erosions

On 3rd an to a lesser extent

4th MTP heads


Update in rheumatoid arthritis

Can we stop therapy in RA?BeST remission/radiographic data at 4 yearsKooij et al. Ann Rheum Dis published online 28 Jul 2008

  • Pt with < 2 yrs of RA treated to DAS 44 score of <2.4 (remission <1.6)

  • As patients went into remission, medications withdrawn

  • Drug free remission more likely to be males, sero-negative, shorter symptom duration before starting therapy

Ra mortality and current therapy michaud k wolfe f arthritis rheum 2005 52 suppl s145

RA Mortality and Current TherapyMichaud K, Wolfe F. Arthritis Rheum 2005;52(suppl)S145

19,580 Pts, 63,811 pt years of observation, Deaths: 33% CV, 22% malignancy, 19% lung

Dl scott on early aggressive therapy scott dl british medical bulletin 2007 81 82 1 97 114

DL Scott on Early Aggressive TherapyScott DL. British Medical Bulletin 2007 81-82(1):97-114

“At present, it seems sensible to focus on trying to rapidly identify patients with the most severe early RA, particularly patients who are sero-positive for rheumatoid factor and have early erosive damage, and give them intensive treatment. There is some evidence, albeit incomplete, that combination therapy using TNF-inhibitors is most effective.”

Rheumatoid arthritis3

Rheumatoid Arthritis

Perioperative Management

Perioperative concerns in ra

Perioperative concerns in RA

  • Postoperative MI

    • RA patients at increased risk of CVD; SMR 2x general population and similar to DM

    • Particularly important in pts with poorly controlled or long standing disease

  • Pulmonary disease

    • Mild asymptomatic abnormalities common

    • Rheumatoid lung disease – fibrosis, bronchiolitis, pleuritis

  • Cricoarytenoid arthritis

    • Up to 75% of patients may be affected via bronchoscopy

    • May affect intubation or cause postop airway obstruction

  • TM joints

Bandi V, Munnur U, Braman SS. Airway problems in patients with rheumatologic disorders. Crit Care Clin 2002;18:749-65

Perioperative concerns

Perioperative Concerns

  • Cervical spine disease:

    • Three types:

      • C1-C2 subluxation

      • Atlantoaxialimpaction

      • Subaxial disease

    • Patients undergoing orthopaedic surgery are a group to worry about. 38% of 154 patients undergoing surgery had evidence of cervical spine disease

    • All pt undergoing orthopaedic surgery for their disease, > 5 yrs of disease, or any neurologic abn warrant cervical spine films flexion/extension views (MRI if abn)



  • Not utilized as intensely as in years gone by

  • Use puts patient at risk for intraop bleeding and postop GI bleeding

    • Sponge weights and suction volumes indicate that NSAID use up to the time of surgery increase blood loss by factor of two and increases transfusion requirements (mortality?)

  • Recommendation is to stop NSAIDs 5 half-lives before surgery

  • ASA should be stopped 10-14 days before surgery

    • What about primary and secondary prophylaxis? Hi risk?



  • Continue for most surgeries

    • Grennan demonstrated fewer infections and flares in group of RA patients who continued Mtxperioperatively

  • Consider temporary stop for:

    • Rising creatinine

    • Post op infection

    • Long period of NPO

    • Patients over 70 yrs

  • Toxiciy: bone marrow suppression, severe stomatitis

    • Rx with folinic acid po or IV

Other non biologic dmards

Other Non-Biologic DMARDs

  • Leflunomide

    • Half-life of 2 weeks

    • 2 studies with opposite conclusions regarding wound healing issues

    • Consider stopping 1 month before surgery where large wounds expected

  • Sulfasalazine – no reason to stop except for NPO

    • May be protective against infection

  • Hydroxychloroquine – no reason to stop

    • Used as postop anticoagulant in years gone by

Tnf agents

TNF Agents

  • Suggest holding for now TNF agent for moderate to intense procedures; continue for minor

  • Hold based on half-life; hold at least 2 half lives

    • Etanercept – half life 3.5-5.5 days

    • Adalimumab – half life10-20 days

    • Infliximab – half life 9.5 days

    • Certolizumab– half life14 days

    • Golumimab – half life14 days

  • Restart 10-14 days postop



  • Exciting changes in the treatment of RA over the last 20 years; most patients will never know how sick they could be!

  • Remember themes

    • Early recognition, early therapy

    • Treat to objective – low disease activity/remission

    • Early institution of biologics/combination therapy

  • Treatments and treatment schemes evolving

  • Login